Ryght AI and QPS Forge Strategic Partnership to Revolutionize Global Clinical Trials

QPS Selects Ryght AI as Exclusive AI Partner for Clinical Trial Optimization and Automation while adding to Ryght's global site network

LAGUNA BEACH, Calif., Jan. 7, 2025 /PRNewswire/ -- Ryght AI, a leading provider of real-time generative AI solutions for the clinical research industry, and QPS Holdings, LLC (QPS), a global contract research organization (CRO), today announced a strategic partnership aimed at transforming clinical trial processes worldwide. Under this agreement, QPS has chosen Ryght AI as its exclusive AI partner to optimize and automate clinical trials on a global scale. Additionally, QPS will bring its extensive network of 750 research sites across 17 countries into the Ryght Research Network, significantly expanding its reach and capabilities.

This collaboration marks a significant milestone in the clinical research industry, combining Ryght AI's cutting-edge AI technology with QPS's vast experience and global presence in clinical trials. The partnership is set to address key challenges in the clinical research sector, including communications, site selection and operational inefficiencies, manual task burdens, and delays in bringing new therapies to market.

Simon Arkell, CEO of Ryght AI, expressed his enthusiasm about the partnership: "We are thrilled to join forces with QPS, one of the most innovative CROs in the world. Their network of 750 research sites will gain a tremendous advantage through our AI-powered solutions. This collaboration exemplifies our shared commitment to accelerating clinical trials and improving patient outcomes globally."

Derek Grimes, Executive Vice President and Global Head of Clinical Research at QPS, highlighted the transformative potential of the partnership: "Ryght AI's unique and powerful platform, coupled with their verticalized AI applications, will be truly transformative in providing real-time communications between QPS and our global network of sites. This will streamline clinical trials from site selection to activation, enrollment, and workflows, ultimately speeding time to market for our biopharma clients. We're excited about the possibilities this partnership brings to enhance our services and drive innovation in clinical research."

The Ryght Research Network, now bolstered by QPS's extensive site network, will leverage advanced generative AI capabilities to deliver real-time insights, empowering sites to make data-driven decisions while ensuring data security. By automating crucial tasks such as feasibility assessments, site selection, and patient referrals, the partnership aims to transform traditional trial workflows, simplifying trial management for research sites and accelerating ideal site and patient selection for sponsors.

This strategic alliance between Ryght AI and QPS represents a significant step forward in addressing the challenges faced by the clinical research industry. By combining AI-driven innovation with global research expertise, the partnership aims to accelerate clinical trial timelines, reduce administrative burdens, and ultimately bring life-saving therapies to patients faster.

About Ryght AI:
Ryght AI, the real-time clinical trials company, is a privately held healthcare technology company providing next-generation safe and secure generative artificial intelligence (GenAI) solutions for the clinical research industry. Ryght's SOC Type 2-compliant platform and customized research applications streamline clinical trials, accelerate workflows, and provide real-time communication for trial sites, sponsors, and CROs.

About QPS:
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. With over 1,100 employees across the US, Europe, and Asia, QPS offers comprehensive pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services.

Media Contact:

Alexia Krispin
[email protected]

SOURCE Ryght